SI-BONE (NASDAQ:SIBN – Get Rating) and Embecta (NASDAQ:EMBC – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk. Profitability This table compares SI-BONE and Embecta’s net margins, return on […]
Shares of SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 12 month target price among […]
Wall Street brokerages forecast that SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) will report sales of $22.37 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for SI-BONE’s earnings. The highest sales estimate is $22.40 million and the lowest is $22.34 million. SI-BONE posted sales of $20.44 million during the […]
SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) insider Anthony J. Recupero sold 577 shares of the business’s stock in a transaction on Monday, April 18th. The stock was sold at an average price of $19.92, for a total value of $11,493.84. Following the completion of the transaction, the insider now directly owns 179,545 shares of the […]
SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) has been assigned an average recommendation of “Buy” from the ten brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokers that […]